PPH – VanEck Pharmaceutical ETF
VanEck Pharmaceutical ETF (PPH) is a Health ETF, issued by VanEck, $1.1B in assets, 0.37% expense ratio.
Returns as of Oct 23, 2026: 1 week +0.5%, 1 year +26.5%.
Invests in U.S.-listed pharmaceutical companies, including mid-caps and foreign firms. Tracks industry-specific benchmark index.
Top holdings
- LLY – Eli Lilly and Company, 21.8%
- MRK – Merck & Company Inc, 13.1%
- NVO – Novo Nordisk A/S, 5.5%
- PFE – Pfizer Inc, 4.9%
- MCK – McKesson Corporation, 4.8%
- GSK – GlaxoSmithKline PLC ADR, 4.7%
- COR – Cencora Inc., 4.5%
- BMY – Bristol-Myers Squibb Company, 4.4%
- TEVA – Teva Pharmaceutical Industries Ltd, 4.4%
- H6D – Haleon PLC, 4.0%
- NVS – Novartis AG ADR, 3.8%
- ABBV – AbbVie Inc, 3.8%
- AZN – AstraZeneca PLC, 3.7%
- JNJ – Johnson & Johnson, 3.4%
- SNY – Sanofi ADR, 3.2%
- TAK – Takeda Pharmaceutical Co Ltd ADR, 2.9%
- ZTS – Zoetis Inc, 2.7%
- VTRS – Viatris Inc, 1.4%
- JAZZ – Jazz Pharmaceuticals PLC, 1.1%
- CORT – Corcept Therapeutics Incorporated, 0.7%
- AXSM – Axsome Therapeutics Inc, 0.6%
- ELAN – Elanco Animal Health, 0.5%
- DFTX – Definium Therapeutics, Inc., 0.4%
- OGN – Organon & Co, 0.3%
- PRGO – Perrigo Company PLC, 0.1%